
    
      Randomized, double-masked, vehicle-controlled, phase 2 study evaluating the efficacy and
      safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term
      treatment of signs and symptoms of Dry Eye Disease (DED). The subjects will be followed for
      approximately 2-3 months from screening to the last visit.
    
  